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Introduction: The advent of biologic medications has increased con-
siderably the potential for treatment benefit in juvenile idiopathic
arthritis (JIA), with clinical remission being now achievable in a sub-
stantial proportion of patients. However, there is a need of data from
the real world of clinical practice to evaluate thoroughly the efficacy
and safety profile of the biologic agents currently approved.
Objectives: To evaluate the outcome of etanercept (ETN) therapy in
Italian children with JIA.
Methods: This is a multicenter, observational study that includes all
children with JIA who were given ETN at Italian pediatric rheumatol-
ogy centers after January 2000. Based on the status of ETN therapy
at study start, patients were classified in 2 groups: patients still re-
ceiving ETN (Group 1); patients discontinued from ETN (Group 2). Pa-
tients in Group 1 underwent both retrospective and cross-sectional
assessments, patients in Group 2 only retrospective assessments.
Outcome of ETN therapy was assessed as follows: a) in Group 1, by
evaluating the state of disease activity at cross-sectional visit through
formal definitions or JADAS10 and cJADAS10 cut-offs; b) in Group 2,
by evaluating reasons for ETN discontinuation. ETN-related side ef-
fects were recorded in both groups.
Results: A total of 1038 patients, 422 in Group 1 and 616 in Group 2
were enrolled in the study. Median treatment duration was 2.5 years
in Group 1 and 2.6 years in Group 2. In group 1, the frequency of in-
active disease (ID) by Wallace criteria was 41.8% and the frequency
of low (or minimal) disease activity (LDA) by Magni-Manzoni criteria
was 63.6%. The frequency of ID, LDA, moderate disease activity, and
high disease activity on JADAS10 was 46.4%, 17.5%, 24.4%, and
11.6%, respectively. The frequency of the same disease activity states
on cJADAS10 was 48.6%, 9.7%, 27.7%, and 14%. In Group 2, reasons
for ETN discontinuation included disease remission (52.4%), lack of
efficacy (29%), and side effects (21.4%).Serious adverse events were
seen in 18 patients of the entire study population and included
inflammatory bowel disease (10 pts), tuberculosis (1 pt), varicella
complicated by purpura fulminans (1 pt), CMV hepatitis (1 pt), acute
pancreatitis (1 pt), papilledema (1 pt), bladder carcinoma (1 pt), thy-
roid carcinoma (1 pt); 1 patient died of streptococcal sepsis.
Conclusion: Around half of the patients treated with ETN achieved
clinical remission and another 10-15% had low disease activity.
Serious adverse events were rare and were mostly represented by
the development of inflammatory bowel diseases.
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Introduction: The goals of medical therapy of patients with Takayasu
arteritis are to control active inflammation and to normalize clinical
and laboratory parameters while preventing further vascular damage.
Corticosteroids and conventional immunosuppressive agents are not
always safe or efficacious. The complex formed by interleukin-6 (IL-6)
and soluble IL-6 receptor appears to play a pivotal role in the patho-
genesis of TA.
Objectives: Herein, we report a child with TA to share the efficacy
and safety of tocilizumab.
Methods: Case report
Results: A- 14-year old girl who fulfilled the classification criteria for TA
was identified. The interval from first symptom onset to diagnosis was
7 months. PVAS at presentation was 13; DEI.Tak was 10 and ITAS2010
was 10. She consisting of thickening of the aortic arch, descending aorta
and superior mesenteric artery wall, obstruction of the right main carotid
artery and superior mesenteric artery failed to respond to corticosteroids,
methotrexate, and cyclophosphamide. After 1 year, she had severe man-
ifestations (blurred vision and severe headache) and elevated both CRP
and ESR the disease, and stenosis of the left vertebral artery in MRI angio
which was considered as relapse. The patient started TCZ infusions
(8 mg/kg for 2 weeks), and a rapid clinical remission was observed, asso-
ciated with a drastic reduction of inflammatory markers. Corticosteroids
were withdrawn, the patient's weight and height improved. 2 months
later, TCZ infusions were extended, with no significant side effects. Ische-
mic manifestations resolved, and new lesions were not observed in MRI
during 8 months on TCZ. At the last follow-up, PVAS was 0, ITAS2010
was 0 and DEI.Tak was 0. ESR was 5 mm/hr, and CRP was 3 mg/dL.
Conclusion: TA in children is a rare but potentially life-threatening
condition. The treatment of TA in children is weak, it is essential to treat
TA aggressively as soon as the diagnosis is secured to reduce mortality
and morbidity. TCZ appears to be effective in the management of pa-
tients with TA, in particular in patients refractory to corticosteroids and/
or conventional immunosuppressive drugs.
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Introduction: Systemic lupus erythematosus in children (juvenile-onset
SLE, jSLE) has an unpredictable course and a more severe phenotype
compared to adults. There are no standards for treatment of jSLE now.
Several studies of B-cell targeted therapy with rituximab (RTX) in adults
have demonstrated its high efficiency in various rheumatic diseases.
Robust data on the use of rituximab in jSLE are still lacking and
dependent on small cohort studies.
Objectives: To evaluate the efficacy and safety of rituximab in children
with jSLE.
Pediatric Rheumatology 2017, 15(Suppl 1):44 Page 125 of 259
